Key Points
- Daniel Karlin sold 5,600 shares of Mind Medicine at an average price of $13.15 on Dec. 26 for $73,640, leaving him with 425,025 shares (a 1.30% reduction in his position).
- Multiple insiders also sold that day — including CEO Robert Barrow (25,791 shares) and Mark Sullivan (11,276 shares) — a clustered insider sell-off that could exert near-term selling pressure.
- MM-120 has moved into Phase III with pivotal readouts expected in 2026, and analysts maintain a consensus "Buy" with an average price target of $30.33 while the stock trades at a market cap of about $1.33 billion.
-inc-logo-1200x675.jpg?v=20240515130629)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) insider Daniel Karlin sold 5,600 shares of the company's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares of the company's stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Mind Medicine (MindMed) Stock Up 3.1%
NASDAQ:MNMD opened at $13.46 on Tuesday. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $14.43. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -6.60 and a beta of 2.57. The stock has a 50-day moving average price of $12.33 and a two-hundred day moving average price of $10.47.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.26). As a group, equities analysts expect that Mind Medicine will post -1.35 earnings per share for the current year.
Institutional Investors Weigh In On Mind Medicine (MindMed)
A number of institutional investors and hedge funds have recently made changes to their positions in MNMD. Marshall Wace LLP boosted its position in Mind Medicine (MindMed) by 31.9% during the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company's stock worth $22,204,000 after purchasing an additional 828,067 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Mind Medicine (MindMed) by 16.2% during the 1st quarter. Wellington Management Group LLP now owns 225,928 shares of the company's stock worth $1,322,000 after buying an additional 31,437 shares during the period. Geode Capital Management LLC grew its stake in Mind Medicine (MindMed) by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company's stock valued at $11,252,000 after buying an additional 66,663 shares during the last quarter. Ally Bridge Group NY LLC raised its holdings in Mind Medicine (MindMed) by 18.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company's stock valued at $2,282,000 after acquiring an additional 59,868 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new stake in Mind Medicine (MindMed) during the second quarter worth approximately $238,000. Institutional investors own 27.91% of the company's stock.
Key Mind Medicine (MindMed) News
Here are the key news stories impacting Mind Medicine (MindMed) this week:
- Positive Sentiment: MM-120 program advancing: MM-120 has moved into Phase III for GAD and MDD with pivotal readouts expected in 2026, a key near-term catalyst that supports upside expectations for revenue-path and valuation. Zacks: MNMD Stock Up, What's In Store for 2026?
- Positive Sentiment: Broker enthusiasm: JonesTrading and other analysts have recently voiced bullish views on the company’s pipeline and growth prospects, which helps lift sentiment and supports higher target prices. Yahoo Finance: JonesTrading Bullish View
- Neutral Sentiment: Analyst mix and institutional ownership: The stock has multiple buy/strong-buy ratings and a wide range of price targets (MarketBeat shows an average target well above current levels) while hedge funds own ~28% — supportive but mixed signals. MarketBeat: MNMD Analyst and Institutional Data
- Negative Sentiment: Insider selling: Several insiders sold shares on Dec. 26 — CEO Robert Barrow sold 25,791 shares (~$339k), Mark Sullivan sold 11,276 shares (~$148k) and Daniel Karlin sold 5,600 shares (~$73.6k). Each sale reduced their holdings by a few percent; while not enormous relative to total float, clustered insider sales can create near-term selling pressure or prompt re-evaluation by some investors. InsiderTrades: MNMD Insider Selling
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on MNMD shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Mind Medicine (MindMed) in a research report on Wednesday, October 8th. Jones Trading began coverage on Mind Medicine (MindMed) in a report on Tuesday, December 23rd. They set a "buy" rating and a $61.00 target price for the company. Royal Bank Of Canada dropped their price target on Mind Medicine (MindMed) from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Friday, November 7th. Chardan Capital upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a report on Wednesday, November 19th. Finally, Needham & Company LLC set a $28.00 price objective on Mind Medicine (MindMed) and gave the stock a "buy" rating in a report on Monday, October 13th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of "Buy" and a consensus price target of $30.33.
View Our Latest Report on MNMD
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.
The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
